Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11,858 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Singer BA, Arnold DL, Drulovic J, Freedman MS, Gold R, Gudesblatt M, Jasinska E, LaGanke CC, Naismith RT, Negroski D, Oh J, Hernandez Perez MA, Selmaj K, Then Bergh F, Wundes A, Ziemssen T, Castro-Borrero W, Chen H, Levin S, Scaramozza M, Shankar SL, Wang T, Wray S. Singer BA, et al. Among authors: oh j. Mult Scler. 2023 Dec;29(14):1795-1807. doi: 10.1177/13524585231205708. Epub 2023 Oct 31. Mult Scler. 2023. PMID: 37905526 Free PMC article.
Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★.
Miller AE, Vermersch P, Kappos L, Comi G, Freedman MS, Oh J, de Seze J, Truffinet P, Benamor M, Purvis A, Wolinsky JS; TOPIC study group. Miller AE, et al. Among authors: oh j. Mult Scler Relat Disord. 2019 Aug;33:131-138. doi: 10.1016/j.msard.2019.05.014. Epub 2019 May 24. Mult Scler Relat Disord. 2019. PMID: 31195337 Free article. Clinical Trial.
Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations.
Freedman MS, Devonshire V, Duquette P, Giacomini PS, Giuliani F, Levin MC, Montalban X, Morrow SA, Oh J, Rotstein D, Yeh EA; Canadian MS Working Group. Freedman MS, et al. Among authors: oh j. Can J Neurol Sci. 2020 Jul;47(4):437-455. doi: 10.1017/cjn.2020.66. Epub 2020 Apr 6. Can J Neurol Sci. 2020. PMID: 32654681 Review.
Productivity loss among people with early multiple sclerosis: A Canadian study.
Rodriguez Llorian E, Zhang W, Khakban A, Patten S, Traboulsee A, Oh J, Kolind S, Prat A, Tam R, Lynd LD. Rodriguez Llorian E, et al. Among authors: oh j. Mult Scler. 2022 Aug;28(9):1414-1423. doi: 10.1177/13524585211069070. Epub 2022 Feb 9. Mult Scler. 2022. PMID: 35137613 Free PMC article.
Prediction of relapse activity when switching to cladribine for multiple sclerosis.
Zhong M, van der Walt A, Monif M, Hodgkinson S, Eichau S, Kalincik T, Lechner-Scott J, Buzzard K, Skibina O, Van Pesch V, Butler E, Prevost J, Girard M, Oh J, Butzkueven H, Jokubaitis V. Zhong M, et al. Among authors: oh j. Mult Scler. 2023 Jan;29(1):119-129. doi: 10.1177/13524585221111677. Epub 2022 Jul 27. Mult Scler. 2023. PMID: 35894247
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, Kalincik T, Van Der Walt A, Yamout B, Lechner-Scott J, Soysal A, Kuhle J, Sanchez-Menoyo JL, Blanco Morgado Y, Spitaleri D, van Pesch V, Horakova D, Ampapa R, Patti F, Macdonell R, Al-Asmi A, Gerlach O, Oh J, Altintas A, Tundia N, Wong SL, Butzkueven H. Spelman T, et al. Among authors: oh j. Mult Scler. 2023 Feb;29(2):221-235. doi: 10.1177/13524585221137502. Epub 2022 Nov 26. Mult Scler. 2023. PMID: 36433775 Free PMC article.
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
Daruwalla C, Shaygannejad V, Ozakbas S, Havrdova EK, Horakova D, Alroughani R, Boz C, Patti F, Onofrj M, Lugaresi A, Eichau S, Girard M, Prat A, Duquette P, Yamout B, Khoury SJ, Sajedi SA, Turkoglu R, Altintas A, Skibina O, Buzzard K, Grammond P, Karabudak R, van der Walt A, Butzkueven H, Maimone D, Lechner-Scott J, Soysal A, John N, Prevost J, Spitaleri D, Ramo-Tello C, Gerlach O, Iuliano G, Foschi M, Ampapa R, van Pesch V, Barnett M, Shalaby N, D'hooghe M, Kuhle J, Sa MJ, Fabis-Pedrini M, Kermode A, Mrabet S, Gouider R, Hodgkinson S, Laureys G, Van Hijfte L, Macdonell R, Oreja-Guevara C, Cristiano E, McCombe P, Sanchez-Menoyo JL, Singhal B, Blanco Y, Hughes S, Garber J, Solaro C, McGuigan C, Taylor B, de Gans K, Habek M, Al-Asmi A, Mihaela S, Castillo Triviño T, Al-Harbi T, Rojas JI, Gray O, Khurana D, Van Wijmeersch B, Grigoriadis N, Inshasi J, Oh J, Aguera-Morales E, Fragoso Y, Moore F, Shaw C, Baghbanian SM, Shuey N, Willekens B, Hardy TA, Decoo D, Sempere AP, Field D, Wynford-Thomas R, Cunniffe NG, Roos I, Malpas CB, Coles AJ, Kalincik T, Brown JWL. Daruwalla C, et al. Among authors: oh j. Mult Scler. 2023 Jun;29(7):875-883. doi: 10.1177/13524585231151951. Epub 2023 Feb 27. Mult Scler. 2023. PMID: 36851894 Free PMC article.
11,858 results
You have reached the last available page of results. Please see the User Guide for more information.